Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs
Seoul, South Korea, December 16, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to accelerate biomarker discovery and optimize translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programs.
Daiichi Sankyo will apply various Lunit SCOPE solutions, including SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis, to explore novel biomarkers and to potentially enrich clinical trials or to potentially support precision patient stratification for select oncology pipeline programs.
“Lunit SCOPE was built to unlock hidden insights from pathology slides - quantifying the tumor microenvironment, predicting molecular profiles and generating data-rich features to inform trial design,” said Brandon Suh, CEO of Lunit. “SCOPE uIHC is now enabling the next generation of IHC-based biomarkers. By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification. Ultimately, this means more efficient trials and better outcomes, where each patient has a greater chance of receiving the therapy that works best for them.”
At a glance
- Company
- Lunit
- Ticker
- KRX: KRX: 328130
- Announcement
- Partnership
- Location
- Seoul, South Korea
Key figures
- Oncology research and development programs
- two
- Oncology assets
- two
People
- Brandon SuhCEO of Lunit
Products and programs
The work will include exploratory research projects and analyses across two oncology assets across multiple types of cancer, with the potential to inform future trial designs, biomarker strategies and clinical development plans.
###
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.
Media Contact
Lunit
Global PR Manager
Jaewhan Lee
[email protected]
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
Questions around this news
What does the collaboration between Lunit and Daiichi Sankyo involve?
The companies plan to use Lunit SCOPE digital pathology tools in two Daiichi Sankyo oncology research and development programs. The work includes exploratory projects and analyses across two oncology assets and multiple cancer types. Findings could inform future trial designs, biomarker strategies, and clinical development plans, but the release describes these as potential outcomes rather than confirmed changes.
How will SCOPE uIHC and SCOPE IO be used in the research?
The release describes SCOPE uIHC as a tool for quantitative immunohistochemistry analysis and SCOPE IO as a tool for immune phenotyping and spatial analysis. Daiichi Sankyo will apply these and other Lunit SCOPE solutions to explore biomarkers. The research could also help identify patients for clinical trials or support precision patient stratification in selected pipeline programs.
What is translational oncology research?
Translational oncology research connects laboratory discoveries with the development and testing of cancer treatments in people. Researchers may study tumor samples, biological mechanisms, or candidate biomarkers to understand how a disease behaves and how a treatment might work. The findings can help shape clinical research, though they do not by themselves establish that a treatment is effective.
How can biomarkers help with clinical trial design?
A biomarker is a measurable biological feature that can provide information about a disease or a person’s response to treatment. In research, investigators may use biomarkers to explore which patients could be more suitable for a study or to group participants for analysis. A biomarker’s usefulness depends on evidence supporting its measurement and interpretation.
Earlier from Lunit
- Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density–Driven Risk Modeling at RSNA 2025
- Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
- Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence
- Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine
- Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025
